Alcon presents its latest in surgery of the Crystal, refractive and surgery in the treatment of diabetic Macular Edema in FacoElche 2013.
– in the last edition of FacoElche 2013, vision care specialists had the opportunity to assess the qualities of innovative products from Alcon
-Alcon introduced the automated injector for intraocular lens AutoSert, the new multifocal AcrySof IQ ReSTOR + 2.5 and AcrySof IQ ReSTOR Toric + 2.5 and the new anti-inflammatory non-steroidal NEVANAC
Elche, 2013 February.- in the last edition of FacoElche, Alcon introduced the automated injector for intraocular lens AutoSert, a new technological breakthrough that allows you to gain control and security during the implantation of intraocular lenses in the Surgery of the Crystal. Alcon also took the opportunity of FacoElche to publicize the new multifocal AcrySof IQ ReSTOR + 2.5 and AcrySof IQ ReSTOR Toric + 2.5 designed to offer more possibilities to be able to choose the intraocular lens most appropriate to each patient according to their way of life and to provide greater clarity in the intermediate vision and far in patients with cataract.
Alcon presented NEVANAC ® the new anti-inflammatory non-steroidal (NSAIDs), an excellent tool for the prevention of Edema Macular post-surgical.
NEVANAC ® is the first NSAID that has been shown to reduce the risk of edema macular pseudofáquico in diabetic and the first with that indication during the first day of FacoElche, held on Thursday, January 31, Dr. L.
Rementeria Alvarez headed a surgery live with the femtosecond laser LenSx ® approved by the FDA and the EC for incisions, capsulotomy and fragmentation of the nucleus in cataract surgery.
On the second day of FacoElche, the J.C.Elvira doctors, J.l.guell and j. Mendicute were responsible for a combined surgery and three of phaco, also live. During surgeries was seen the effectiveness of teams Constellation and Infiniti Vision System using energy torzional OZil ® and AutoSert ®. Also were the most advanced lenses of AcrySof ® family, such as the IQ Toric T2 for the correction of astigmatism, the new IQ ReSTOR ® + 2.5 or IQ ReSTOR ® Toric, multifocal lens for the correction of astigmatism.
About Alcon
Alcon, a world leader in vision care, commercialized innovative products that improve the quality of life helping people around the world see better.
The three areas of Alcon, surgery, pharmacy and Vision Care, offer the broadest spectrum of products for eye health around the world. Alcon is the second largest division of the Novartis group, with sales of 10 billion dollars in 2011. Headquartered in Fort Worth, Texas (USA). (UU.), Alcon has a staff of 24,000 people in around the world, operates in 75 countries and its products are sold in 180 markets.
In Spain, Alcon has been working at the service of Ophthalmology, with vocation of service to the professionals and in a spirit of care for the vision of people for over a hundred years. Alcon Spain currently has more than 600 employees and is headquartered in El Masnou.
About Novartis
Novartis AG (NYSE: NVS) provides solutions for the health care needs of patients and societies. Focused exclusively on the area of health, offers a broad portfolio of products to meet these needs: innovative medicines; vision care; generic drugs of high quality to cost savings; human vaccines and diagnostic tools; OTC; and Animal health. Novartis is the only company that has achieved a leading position in these areas. In 2011 the Group attained a turnover of USD $ 58,600 million and invested approximately 9,600 million dollars (9,200 million dollars excluding impairment for the depreciation of assets and depreciation) in r & d activities. Headquartered in Basel, Switzerland, Novartis group companies employs approximately 124,000 people have and are present in more than 140 countries around the world.
